Jubilant Ingrevia Limited (JUBLINGREA) — Financial Results | 22 July 2026(3 announcements)

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF
📢 Key Event
Jubilant Ingrevia reported Q1 FY27 results with 25% YoY revenue growth to ₹1,300 crore and 36% YoY EBITDA growth to ₹209 crore.
🔄 What Changed
EBITDA margin expanded to 16% from 15% in Q4 FY26; Nutrition segment achieved highest EBITDA in three years.
🔮 What's Next
New Multi-Purpose Plant commissioning on track for end of current calendar year; evaluating opportunities in Electronics & Semiconductors, Cosmetics, Nutrition
💡 Investor Takeaway
Strong margin expansion and segmental growth support long-term value creation in high-margin specialty and CDMO segments.

Jubilant Ingrevia reported Q1 FY27 revenue of ₹1,300 crore, up 25% YoY and 10% QoQ, with EBITDA rising 36% to ₹209 crore and net profit at [amount not verified]. EBITDA margin expanded to 16% from 15% in the prior quarter, driven by volume growth and pricing gains across Specialty Chemicals, Nutrition, and Chemical Intermediates. Specialty Chemicals contributed ₹533 crore (41% of revenue) with 27% EBITDA margin, while Nutrition achieved its highest EBITDA in three years at ₹36 crore. The company advanced its Pinnacle Journey strategy, targeting CDMO expansion and new product pipelines, including 25+ confirmed molecules with ₹3,500+ crore peak revenue potential. Strategic milestones included CDMO integration and ESG recognitions, supporting long-term growth in high-margin segments.

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF
MetricValue
Revenue₹1,300 Cr
Net Profit (PAT)₹106 Cr
📢 Key Event
Jubilant Ingrevia reports Q1 FY27 revenue of ₹1,300 crores, up 25% YoY, with EBITDA at ₹209 crores (+36% YoY) and PAT at ₹106 crores (+41% YoY).
🔄 What Changed
Revenue grew 25% YoY to ₹1,300 crores; EBITDA grew 36% YoY to ₹209 crores; PAT grew 41% YoY to ₹106 crores; specialty chemicals contributed 41% of revenue with 26% EBITDA margin.
🔮 What's Next
Commissioning of the new Multi-Purpose Plant by end of current calendar year; FY27 growth target supported by Specialty Chemicals and Nutrition; ₹100 crores lean savings target.
💡 Investor Takeaway
Strong top-line and bottom-line growth with margin expansion across key segments, signaling robust execution of the Pinnacle Vision strategy.

Jubilant Ingrevia reported Q1 FY27 revenue of ₹1,300 crores (+25% YoY), EBITDA of ₹209 crores (+36% YoY), and PAT of ₹106 crores (+41% YoY), driven by specialty chemicals (26% margin), nutrition (15% margin), and chemical intermediates (11% margin). The company highlighted progress on its Pinnacle Vision strategy, with a new multi-purpose plant on track for commissioning by year-end, and strong growth in North America and Europe contributing 37% of revenue. Management expects FY27 growth to continue, targeting ₹100 crores in lean savings and pipeline milestones in electronics, cosmetics, and nutrition.

3 Financial Results 🔴 High Importance Neutral 📄 PDF
MetricValue
Revenue₹1.31 L Cr
Net Profit (PAT)₹12,622 Cr
📢 Key Event
Board approved unaudited consolidated financial results for Q1 FY2026
🔮 What's Next
No forward guidance provided in the filing
💡 Investor Takeaway
Strong top-line growth and margin stability support near-term outlook, but limited review scope may restrict full confidence in subsidiary data.

Jubilant Ingrevia Limited reported unaudited consolidated revenue of ₹125,265 crores for Q1 FY2026, up sharply from ₹112,912 crores prior, driven by strong performance across specialty chemicals and nutrition segments. Net profit surged to ₹12,622 crores, with operating margin holding steady at 11.39%, while net profit margin improved to 8.07%. The Board approved results reviewed by Walker Chandiok & Co LLP, noting limited scope on subsidiaries and no material misstatements found. Debt ratios remain stable, with interest coverage at 11.39x and bad debts at 0%.

About Jubilant Ingrevia Limited (JUBLINGREA)

Chemicals · Chemicals · Listed on NSE

Market Cap: ₹10,740.33 Cr P/E: 34.5 ROE: 9.6% ROCE: 11.7% Div Yield: 0.37%

View full JUBLINGREA stock details →

📡 Get AI alerts when JUBLINGREA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JUBLINGREA — Free

📊 More JUBLINGREA filings

See all JUBLINGREA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JUBLINGREA files new disclosures

Track JUBLINGREA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JUBLINGREA — Free

Free account · 2 AI queries/day